Skip to main content
OTCMKTS:HKMPY

Hikma Pharmaceuticals Stock Forecast, Price & News

$67.89
0.00 (0.00 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$67.89
▼
$67.89
50-Day Range
$59.02
▼
$67.89
52-Week Range
$55.86
▼
$73.13
Volume38 shs
Average Volume2,162 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HKMPY News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Hikma Pharmaceuticals logo

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Headlines

Hikma Pharmaceuticals PLC -- Moodys withdraws Hikmas ratings for business reasons
Hikma Pharmaceuticals PLC -- Moody's withdraws Hikma's ratings for business reasons
April 21, 2021 |  finance.yahoo.com
What Is The Ownership Structure Like For Hikma Pharmaceuticals PLC (LON:HIK)?
What Is The Ownership Structure Like For Hikma Pharmaceuticals PLC (LON:HIK)?
March 21, 2021 |  finance.yahoo.com
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brothers Brother Foundation and the National Childrens Cancer Society
Hikma Donates Over $4 Million USD in Medicines and Signs New Long-term Partnerships with Dispensary of Hope, Direct Relief, Americares, Brother's Brother Foundation and the National Children's Cancer Society
February 18, 2021 |  finance.yahoo.com
Heres Why I Think Hikma Pharmaceuticals (LON:HIK) Is An Interesting Stock
Here's Why I Think Hikma Pharmaceuticals (LON:HIK) Is An Interesting Stock
December 28, 2020 |  finance.yahoo.com
Hikma launches generic Advair Diskus® following FDA approval
Hikma launches generic Advair Diskus® following FDA approval
December 17, 2020 |  finance.yahoo.com
MGE Energy Issues December 2020 Interim Report
MGE Energy Issues December 2020 'Interim Report'
December 15, 2020 |  finance.yahoo.com
MGE Energy Issues Third-Quarter Financial Update
MGE Energy Issues Third-Quarter Financial Update
November 6, 2020 |  finance.yahoo.com
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
Hikma and Arecor expand collaboration with new agreement to develop and commercialise ready-to-administer medicine
October 20, 2020 |  feeds.benzinga.com
Hikma Pharmaceuticals Plc ADR (HKMPY)
Hikma Pharmaceuticals Plc ADR (HKMPY)
October 20, 2020 |  nasdaq.com
Who Has Been Buying MGE Energy, Inc. (NASDAQ:MGEE) Shares?
Who Has Been Buying MGE Energy, Inc. (NASDAQ:MGEE) Shares?
October 16, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HKMPY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.hikma.com
Phone+44-20-73992760
Employees8,600
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.44 out of 5 stars

Medical Sector

1717th out of 2,038 stocks

Drug Manufacturers - Specialty & Generic Industry

55th out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Hikma Pharmaceuticals (OTCMKTS:HKMPY) Frequently Asked Questions

What stocks does MarketBeat like better than Hikma Pharmaceuticals?

Wall Street analysts have given Hikma Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hikma Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Hikma Pharmaceuticals' stock price been impacted by Coronavirus?

Hikma Pharmaceuticals' stock was trading at $48.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HKMPY stock has increased by 41.4% and is now trading at $67.89.
View which stocks have been most impacted by COVID-19.

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 64, Pay $3.01M)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 52, Pay $3.72M)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 63, Pay $2.16M)
  • Mr. Khalid Waleed Hosny Al Nabilsi, Chief Financial Officer (Age 49)
  • Ms. Henriette Nielsen, Exec. VP of Bus. Operations
  • Dr. Shahin Fesharaki, Chief Scientific Officer
  • Mr. Hussein Arkhagha, Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan, Exec. VP of Corp. Devel. and M&A (Age 56)
  • Ms. Susan Ringdal, Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi, Exec. VP of Organisational Devel.

Who are some of Hikma Pharmaceuticals' key competitors?

Some companies that are related to Hikma Pharmaceuticals include (THCX.V) (THCX), 31444 (GLH), 438280 (ACG), 815446 (HC), Abacus Health Products (ABAHF), Acreage (ACRGF), Althea Group (AGH), Applied Biosciences (APPB), AusCann Group (AC8), Ayr Strategies (AYRSF), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), Can B (CANB), Cannara Biotech (LOVE) and CannPal Animal Therapeutics (CP1).
View all of HKMPY's competitors.

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPY."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPY stock can currently be purchased for approximately $67.89.

How many employees does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals employs 8,600 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

Where are Hikma Pharmaceuticals' headquarters?

Hikma Pharmaceuticals is headquartered at 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


This page was last updated on 5/14/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.